Pre-clinical studies with a FAK inhibitor (VS-4718) in a PDAC mouse model demonstrated diminished tumor fibrosis, inhibited tumor progression, increased effectiveness of chemotherapy (Gemcitabine), and an augmented responsiveness to immunotherapy (αPD1) attributed to higher levels of infiltrating CD8+ cytotoxic T lymphocytes (Jiang et al., 2016). The gene discussed is CD8A; the disease is neoplasm.